In 2023, West Virginia had the highest share of adults (**** percent) who had ever been told by a doctor that they had diabetes. This statistic represents the percentage of adults in the United States who had ever been diagnosed diabetes as of 2023, by state.

United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

It was estimated that as of 2023, around 25.3 million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for three percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around 53 million men and 44 million women in the United States had prediabetes. However, according to the CDC, around 80 percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around 8.6 percent of adults in the United States had been diagnosed with diabetes, an increase from six percent in the year 2000. Diabetes is much more common among older adults, with around 21 percent of those aged 60 years and older diagnosed with diabetes, compared to just two percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around 18 percent of adults have been diagnosed with diabetes.

In 2024, there were almost 1.58 million people who were newly diagnosed with diabetes in the United States. This statistic represents the number of new cases of diagnosed diabetes among U.S. adults per year from 2000 to 2024, in thousands of people.

In 2023, the prevalence of diagnosed diabetes in the United States among people aged 18 and over amounted to *** percent. This was an increase from *** percent in the year 2000. How many people in the United States have diabetes? It was estimated that in 2023, almost **** million people in the United States had been diagnosed with diabetes. The number of people living with diabetes has increased over the past few decades, with only **** million people living with diabetes in the year 1980. Diabetes in the United States is more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to ** percent of those aged 40 to 59 years. Leading diabetic states In 2023, the U.S. states with the highest prevalence of diagnosed diabetes were West Virginia, Mississippi, and Louisiana. Just over ** percent of adults in West Virginia had diabetes that year. In Utah, just under ***** percent of adults have been diagnosed with diabetes, the lowest share in the United States.

In the period from January 2017 to March 2020, it was estimated that 16.8 percent of non-Hispanic Black adults in the United States had either diagnosed or undiagnosed diabetes. This statistic shows the percentage of adults in the United States with diagnosed or undiagnosed diabetes, by race/ethnicity.

In 2021, there were almost 29 births to American Indian or Alaska Native mothers with prepregnancy diabetes in the United States per 1,000 live births. This was an increase from a rate of 21 cases of prepregnancy diabetes per 1,000 live births among this group in the year 2016. This statistic shows the rate of prepregnancy diabetes in the United States in 2016 and 2021, by race and ethnicity.

The average for 2021 based on 20 countries was 8.73 percent. The highest value was in Mexico: 16.9 percent and the lowest value was in Ecuador: 4.4 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

Diabetes prevalence in Massachusetts has been steadily increasing.

Based on data from January 2017 to March 2020, it was estimated that around 41 percent of men and 32 percent of women in the United States had prediabetes. Those with prediabetes have blood sugar levels higher than normal, but not high enough to yet be diagnosed with diabetes. This statistic shows the percentage of adults in the United States with prediabetes, by gender.

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by the rising prevalence of diabetes and an aging population. The market, valued at approximately $25.16 billion in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors: increasing adoption of continuous glucose monitoring (CGM) systems offering improved diabetes management, technological advancements leading to smaller, more user-friendly devices, and growing awareness of the benefits of proactive diabetes care. The market is segmented into monitoring and management devices. Within monitoring, self-monitoring blood glucose (SMBG) devices, including glucometers, test strips, and lancets, remain a substantial portion, although CGM is experiencing faster growth due to its real-time data capabilities and improved patient outcomes. The management device segment is dominated by insulin delivery systems like insulin pumps, syringes, pens, and jet injectors, with insulin pumps showing particularly strong growth prospects due to their convenience and efficacy in managing insulin delivery. Competitive intensity is high, with major players like Abbott, Medtronic, Dexcom, and Novo Nordisk vying for market share through continuous innovation and strategic partnerships. The North American region, particularly the US, holds a significant market share owing to high diabetes prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative medical technologies. The market's growth trajectory is expected to remain positive through 2033, although certain restraints could influence the pace. These include high costs associated with some devices, particularly CGMs and insulin pumps, creating access barriers for some patients. However, increasing insurance coverage and the development of more affordable alternatives are mitigating these challenges. Furthermore, technological advancements, such as the integration of artificial intelligence and machine learning in diabetes management, are expected to further enhance the market's potential. Companies are focusing on developing integrated systems that combine CGM with insulin delivery, providing a more holistic approach to diabetes management. This trend will likely drive further growth and consolidation within the market. Future success will depend on companies' ability to innovate, offer competitive pricing strategies, and address the evolving needs of patients. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Growing Diabetes and Obesity Population in the United States.

In 2023, there were 22.4 deaths from diabetes mellitus per 100,000 people in the United States. The death rate caused by this condition has fluctuated over the past decades, reaching almost 26 deaths per 100,000 people in the early 2000s, and about 18 deaths in 1980. Prevalence of diabetes In 2022, around 8.4 percent of the adult population in the U.S. had diabetes. In total, around 38 million adults in the United States are currently living with diabetes. Of this total, the vast majority were aged 45 years and older. The states with the highest share of adults with diabetes are West Virginia, Mississippi, and Louisiana. Cure for diabetes? Researchers are helping diabetics put their Type 2 diabetes into remission, where the blood sugar levels are kept within a healthy range. For Type 1, scientists are looking for ways to prevent the immune system’s attack on beta cells, which causes diabetes. These cells, located in the pancreas, produce the insulin people need to live. As of yet, there is no cure for diabetes mellitus; however, scientists are researching ways to make diabetes harmless one day.

The Report Covers US Diabetes Devices Companies and It is Segmented by Management Devices (insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Insulin Disposable Pens, and Jet Injectors) and Monitoring Devices (self-Monitoring Blood Glucose and Continuous Glucose Monitoring). The Report Offers the Value (in USD) for the Above Segments.

The North America Diabetes Drugs Market Report is Segmented by Drug Class (Insulins [Biosimilar Insulin and More], Non-Insulin Injectable, Oral Anti-Diabetic and Combination Drugs), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Drug Origin (Branded and Generic/Biosimilar), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).

The Report Covers United States Diabetes Care Drugs Market Companies and It is Segmented by Drugs (Oral Anti-Diabetic Drugs, Insulin, Non-insulin Injectable Drugs, And Combination Drugs). The Report Offers the Value (in USD) and Volume (in Unit) for the Above Segments.

Based on data from January 2017 to March 2020, it was estimated that around 36 percent of non-Hispanic white adults in the United States had prediabetes. Those with prediabetes have blood sugar levels higher than normal, but not high enough to yet be diagnosed with diabetes. This statistic shows the percentage of adults in the United States with prediabetes from 2017 to 2020, by race/ethnicity.

Diabetes Treatment Market Outlook

The global diabetes treatment market size was valued at approximately $50 billion in 2023 and is projected to reach around $90 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5%. This significant growth is primarily driven by the increasing prevalence of diabetes worldwide, advancements in medical technology, and a rising awareness of diabetes management and treatment options.

One of the primary growth factors for the diabetes treatment market is the increasing prevalence of diabetes globally. According to the International Diabetes Federation, the number of people with diabetes is expected to rise from 463 million in 2019 to 700 million by 2045. This alarming increase highlights the urgent need for effective diabetes management and treatment solutions, driving demand in the market. Additionally, lifestyle changes such as urbanization and diet shifts contribute to the rising diabetes rates, further fueling market growth.

Technological advancements in diabetes treatment are another significant growth catalyst. Innovations in insulin delivery systems, continuous glucose monitoring (CGM) devices, and artificial pancreas systems are transforming diabetes care. Improved accuracy, convenience, and patient compliance offered by these technologies enhance diabetes management, thereby boosting market demand. The integration of digital health technologies, such as mobile health apps and telemedicine, also plays a crucial role in supporting diabetes management and monitoring, propelling market growth.

Government initiatives and supportive policies are also driving the growth of the diabetes treatment market. Many governments across the globe are implementing national diabetes programs to improve diabetes care and management. These programs often include funding for research, subsidies for diabetes medications and devices, and public awareness campaigns. Furthermore, collaborations between public and private sectors are fostering innovation and accessibility in diabetes treatment, which is expected to sustain market growth over the forecast period.

From a regional perspective, North America holds a significant share of the diabetes treatment market due to the high prevalence of diabetes, well-established healthcare infrastructure, and strong presence of key market players. Europe follows closely, driven by a growing diabetic population and favorable reimbursement policies. The Asia Pacific region is anticipated to witness the fastest growth, attributed to increasing urbanization, rising healthcare expenditure, and a large undiagnosed diabetic population. Meanwhile, Latin America and the Middle East & Africa regions are expected to experience steady growth owing to improving healthcare access and growing awareness of diabetes management.

Product Type Analysis

In the diabetes treatment market, the product type segment is categorized into Insulin, Oral Hypoglycemic Agents, Non-Insulin Injectable Drugs, and Others. Insulin remains a cornerstone in diabetes management, particularly for individuals with Type 1 diabetes and advanced Type 2 diabetes. The development of various insulin formulations, such as rapid-acting, long-acting, and premixed insulins, caters to the diverse needs of diabetic patients. Additionally, innovations like insulin pens and pumps enhance the convenience and accuracy of insulin administration, supporting the growth of this segment.

Oral Hypoglycemic Agents (OHAs) represent another critical segment in diabetes treatment, particularly for Type 2 diabetes management. OHAs include medications such as metformin, sulfonylureas, DPP-4 inhibitors, and SGLT-2 inhibitors, which help to lower blood glucose levels through different mechanisms. The increasing prevalence of Type 2 diabetes, along with a growing focus on combination therapies to improve glycemic control, is driving the demand for OHAs. Additionally, the development of new classes of oral medications with improved efficacy and safety profiles is expected to further boost this segment.

Non-Insulin Injectable Drugs, including GLP-1 receptor agonists and amylin analogs, offer alternative treatment options for diabetes management. These injectable drugs help to control blood sugar levels and provide additional benefits such as weight loss and cardiovascular protection. The growing preference for non-insulin injectables among patients and healthcare providers is contributing to the expansion of this segment. Moreover, ongoing research and development efforts aimed at enhancing the delivery and efficacy of these

The North America Diabetes Care Devices Market report segments the industry into Product (Monitoring Devices, Management Devices) and Geography (United States, Canada, Rest of North America). Get five years of historical data alongside five-year market forecasts.

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion, at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of diabetes, fueled by an increasing geriatric population. This demographic trend, coupled with the underdiagnosis of the condition, presents both opportunities and challenges for market participants. The large, untapped population of undiagnosed individuals represents a significant market opportunity for innovative diagnostic solutions. However, the low diagnosis rate also poses a challenge, as untreated diabetes can lead to severe health complications and increased healthcare costs. The geriatric population, with its higher susceptibility to diabetes, further exacerbates this challenge.
To capitalize on the market opportunities and navigate these challenges effectively, companies must focus on developing innovative diagnostic tools and effective patient education programs. By addressing the unmet needs in diabetes diagnosis and management, market participants can differentiate themselves and capture a larger share of this growing market.

What will be the Size of the Type 2 Diabetes Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by advancements in diabetes management, public health, and weight management. Pancreatic beta-cell destruction and the subsequent need for insulin therapy remain at the forefront of market dynamics. Diabetes burden is a significant concern, with diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy posing significant health risks. SGLT2 inhibitors have emerged as a promising treatment option, addressing both glycemic control and cardiovascular disease. Healthcare access and access to care are crucial factors shaping the market. Global health initiatives and healthcare costs are influencing the development of diabetes technology, including insulin delivery devices, glucose sensors, and remote monitoring.

Precision medicine, data analytics, and machine learning are transforming diabetes education and patient engagement. Lifestyle modifications, such as dietary changes and physical activity, remain essential components of diabetes management. Insulin resistance, insulin therapy, and HbA1c testing continue to be key areas of focus in the medical device industry. Ongoing research in areas like Genetic Testing, Stem Cell Therapy, and primary care physician engagement is further shaping the market. Health disparities, early detection, and glycemic control are critical public health concerns. Diabetes prevention and healthcare provider collaboration are essential to improving health outcomes. The market is continually unfolding, with ongoing drug development, clinical trials, and advancements in diabetes technology driving innovation.

How is this Type 2 Diabetes Industry segmented?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

.

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a complex condition characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to elevated blood glucose levels. Metabolic syndrome, an autoimmune disease, and a precursor to type 2 diabetes, affects millions worldwide. The medical device industry is responding with innovative solutions, such as artificial pancreas systems and insulin delivery devices, to improve glycemic control and enhance quality of life. Artificial intelligence and machine learning are revolutionizing diabetes management by facilitating early detection, personalized treatment plans, and remote monitoring. Diabetes burden is significant, with complications including diabetic foot ulcers, diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy.

Prevention and management involve lifestyle modifications, such as dietary changes and physical activity, as well as pharmacological interventions, including oral antidiabetic medications, insulin therapy, and newer classes like GLP-1 receptor a

As of 2021, there were an estimated five million women in the United States with diabetes who had not yet been diagnosed. All together, there were some 29.4 million adults in the United States who had been diagnosed with diabetes as of that time. This statistic shows the estimated number of adults with diabetes in the United States as of 2021, by gender.